Biosimilar method transfer failure across labs during stability pull comparisons: FDA/EMA expectations for root cause, rework, and comparability justification



Published on 31/12/2025

Understanding Root Causes of Biosimilar Method Transfer Failure Across Labs During Stability Pull Comparisons

Biosimilars are crucial for expanding treatment options in pharmaceuticals, but method transfer failures across different labs during stability pull comparisons can significantly undermine their reliability. These failures can lead to deviations, out-of-specification (OOS) results, and regulatory scrutiny from bodies such as the FDA, EMA, and MHRA. This article provides a structured approach to investigating these failures, enabling pharmaceutical professionals to determine root causes effectively. Readers will learn how to respond swiftly, analyze the situation rigorously, and implement corrective and preventive actions.

By following this detailed investigative framework, you will enhance your organization’s capability to maintain compliance and assure the quality of biosimilars, thereby safeguarding both the manufacturing process and overall product integrity.

Symptoms/Signals on the Floor or in the Lab

Recognizing early signals of method transfer failure is critical. Symptoms may emerge through various channels, recommending immediate attention to the process. Here are typical indicators observed on

the manufacturing floor or laboratory:

  • Inconsistent Results: Discrepancies in stability data compared to previous lab results can signal method transfer failure.
  • Deviation Reports: An increased number of deviation reports specifically related to stability tests may indicate underlying issues.
  • Quality Control Flags: QC teams often raise flags when results deviate from established acceptable ranges.
  • User Feedback: Scientists and technicians mentioning difficulties in replicating results point towards potential methodological discrepancies.

Effective communication among team members is paramount. Documenting these signals promptly can support future investigations and CAPA measures.

Likely Causes (by category: Materials, Method, Machine, Man, Measurement, Environment)

When faced with apparent method transfer failures, categorizing potential causes can help streamline the investigative process. Each of the following categories can serve as a basis for further exploration:

  • Materials: Variations in reagents or sample quality could lead to inconsistent results. Ensure all labs utilize the same materials, from raw ingredients to standards used in the stability study.
  • Method: Variations in methodologies across labs (e.g., different assay techniques, temperature control variations) can lead to discrepancies.
  • Machine: Calibration issues or differences in equipment across labs may impact the consistency of outcomes.
  • Man: Differences in training and competence among laboratory personnel can introduce variability, particularly in sample handling and analysis.
  • Measurement: Inconsistencies in measurement techniques (e.g., variances in assay sensitivity) may also contribute to discrepancies in data.
  • Environment: Environmental conditions such as humidity, temperature, and contamination levels need to be assessed; these can all influence stability test results.
Pharma Tip:  Biosimilar potency OOS vs reference product after downstream resin change: CAPA strategy to restore similarity and prevent regulatory delays

Immediate Containment Actions (first 60 minutes)

Initial containment actions are crucial to prevent further impacts on product quality and regulatory compliance. Here are essential steps to undertake within the first hour of detecting a method transfer issue:

  • Isolate the Affected Batch: Cease any ongoing stability testing for affected batches to prevent further issues, ensuring they cannot impact ongoing quality evaluations.
  • Notify Relevant Teams: Inform cross-functional teams including production, quality control, quality assurance, and regulatory affairs regarding the occurrence to initiate a rapid response.
  • Document Events: Ensure a detailed timeline of events is recorded, capturing deviations, observed symptoms, and actions taken. Documentation will be vital for comprehensive investigations.
  • Evaluate Product Status: Assess the product and its testing status to determine the potential impact on safety, efficacy, or compliance with specifications and regulations.

Investigation Workflow (data to collect + how to interpret)

The investigation of method transfer failures necessitates a systematic approach to data collection and analysis. The following workflow outlines actionable steps:

  1. Gather Initial Data: Collect all related documentation, including batch records, standard operating procedures (SOPs), and stability data across labs.
  2. Identify Variances: Compare results from different labs and highlight deviations in numerical data, procedures followed, and environmental conditions during testing.
  3. Conduct Interviews: Engage with personnel from each impacted lab to gather insights on their procedures, perspectives on the discrepancies observed, and any commonalities or differences in their methods.
  4. Document Findings: Compile a report of the investigation process, noting all data, actions taken, personnel involved, and timelines.

Root Cause Tools (5-Why, Fishbone, Fault Tree) and when to use which

Utilizing root cause analysis tools expedites identifying underlying problems. Here’s an overview of effective tools and their appropriate applications:

Tool Description When to Use
5-Why Analysis A method where you ask ‘why’ repeatedly (typically five times) to drill down to the root cause of an issue. Use when a specific symptom is apparent and requires thorough exploration to identify underlying causes.
Fishbone Diagram Visual tool categorizing potential causes of a problem, helping teams brainstorm in structured categories. Suitable for group discussions to identify multiple causes and their relationships in complex issues such as method transfer failures.
Fault Tree Analysis A top-down, deductive failure analysis that focuses on various failure pathways leading to specific undesired events. Use for a comprehensive understanding of potential failure modes, especially when multiple factors are believed to contribute.
Pharma Tip:  Biosimilar stability comparability failure during biosimilar development: how to build a defensible similarity narrative with data integrity controls

CAPA Strategy (correction, corrective action, preventive action)

Implementing a robust Corrective and Preventive Action (CAPA) strategy is essential following an investigation into method transfer failures. Components of this strategy should include:

  1. Corrections: Address immediate issues by correcting any discrepancies in testing methods or results that led to the failure.
  2. Corrective Actions: Based on root cause analysis, outline actions to eliminate identified causes, such as training personnel on uniform methodologies or calibrating equipment regularly.
  3. Preventive Actions: Establish protocols and controls to prevent future occurrences, including SOP revisions, process validations, or enhanced monitoring during stability testing.

Control Strategy & Monitoring (SPC/trending, sampling, alarms, verification)

A proactive control strategy is vital to monitor the stability of biosimilars effectively. Important elements to include are:

  • Statistical Process Control (SPC): Implement SPC methods to monitor trends, facilitating real-time identification of deviations through control charts.
  • Sampling Strategies: Design robust sampling plans that ensure representative data collection across different labs and conditions.
  • Alarms and Alerts: Establish automated alerts for outlying results during stability testing to prompt immediate investigation.
  • Verification Processes: Regularly verify testing results against established standards to reinforce confidence in the method transfer.

Validation / Re-qualification / Change Control impact (when needed)

Following identified issues and implemented CAPAs, it is crucial to assess potential impacts on validation, re-qualification, and change control. Key considerations include:

  • Validation Review: Review existing biosimilar validation protocols to ensure they accommodate any changes prompted by investigation findings.
  • Re-qualification of Methods: If method discrepancies are resolved, execute necessary re-qualification or re-validation to confirm reliability across all labs.
  • Change Control Procedures: Ensure that any changes made to methods, materials, or processes undergo rigorous change control review and documentation.

Inspection Readiness: what evidence to show (records, logs, batch docs, deviations)

Regulatory inspections can occur at any point, necessitating preparedness to demonstrate regulatory compliance. Evidence needed includes:

Pharma Tip:  Biosimilar aggregate level increase after cell line or upstream change: CAPA strategy to restore similarity and prevent regulatory delays

Related Reads

  • Records and Logs: Maintain comprehensive records of all investigations, CAPAs, and associated documentation reflecting responses to incidents.
  • Batch Documentation: Ensure all batch production and quality control records are readily available for review.
  • Deviation Reports: Keep thorough logs of any deviation from standard processes and how these were handled.

FAQs

What should I do if I observe inconsistent stability results across labs?

Immediately initiate deviation reporting, notify relevant parties, and follow containment procedures to isolate the affected batches.

How often should training regarding method transfer protocols be conducted?

Training should occur regularly and whenever process changes arise; consider additional training following significant deviations or issues.

What documentation is essential during an investigation?

Documentation should include deviation reports, stability data, investigation notes, interviews with personnel, and CAPA records.

What are the regulatory implications of failed method transfers?

Regulatory bodies may scrutinize product quality and safety, warranting thorough investigations and potentially leading to compliance actions.

How can we prevent future method transfer failures?

Implement systematic training, uniform methodologies, consistent equipment calibration, and robust documentation practices.

Is it necessary to notify regulatory authorities about method transfer failures?

Yes, if the failure has a significant impact on product quality or safety, it is imperative to notify the relevant regulatory authorities following established guidelines.

What role does statistical process control play in method transfer?

SPC enables the continuous monitoring of processes, making it easier to detect variations or trends that may indicate method transfer issues early.

How important is inter-laboratory communication in method transfers?

Cohesive communication is critical to ensure everyone follows uniform protocols, understands procedures, and shares observations to mitigate risks across labs.

When is re-validation necessary?

Re-validation is necessary when any changes to processes, methodologies, or equipment occur that may impact product quality or compliance.

What is meant by deviation investigation?

A deviation investigation is a structured analysis of unexpected or non-conforming results to identify the root cause and implement corrective actions.

Why is a control strategy vital for stability testing?

A solid control strategy ensures consistent monitoring of product quality, minimizes risks, and supports compliance during stability testing processes.